THE COST-EFFECTIVENESS OF HIV TESTING OF PHYSICIANS AND DENTISTS IN THE UNITED-STATES

被引:28
|
作者
PHILLIPS, KA
LOWE, RA
KAHN, JG
LURIE, P
AVINS, AL
CICCARONE, D
机构
[1] UNIV CALIF SAN FRANCISCO,SCH MED,INST HLTH POLICY STUDIES,SAN FRANCISCO,CA 94143
[2] UNIV CALIF SAN FRANCISCO,SCH MED,DEPT EPIDEMIOL & BIOSTAT,SAN FRANCISCO,CA 94143
[3] UNIV CALIF SAN FRANCISCO,SAN FRANCISCO GEN HOSP,DIV GEN INTERNAL MED,SAN FRANCISCO,CA
[4] UNIV CALIF BERKELEY,CTR STUDENT HLTH,BERKELEY,CA
来源
关键词
D O I
10.1001/jama.271.11.851
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective.-To evaluate the cost-effectiveness of alternative policies for human immunodeficiency testing (HIV) testing of physicians and dentists. Methods.-Decision analysis and cost-effectiveness analysis from a societal perspective were used. Data were derived from extensive literature review and consultation with experts. We conducted sensitivity analyses and also performed a cost-benefit analysis. Analyses.-We analyzed policies for mandatory or voluntary testing of all physicians, surgeons, and dentists; for those testing positive, we analyzed mandatory or voluntary exclusion from practice, restriction from performance of invasive procedures, or requirements to inform patients of serostatus. Main Outcome Measure.-Cost per patient infection averted. Results.-Although one-time mandatory testing of surgeons and dentists with mandatory restriction of those found to be HIV-positive is more cost-effective than other policies, the cost-effectiveness varies tremendously under different scenarios. Results were highly sensitive to several data inputs, especially HIV seroprevalence of surgeons and dentists and transmission risk. For example, under a medium seroprevalence and transmission risk scenario, mandatory testing of all surgeons might avert 25 infections at a total cost of $27.9 million or $1 115 000 per infection averted and an incremental cost of $291 000 compared with current testing; however, the incremental cost-effectiveness per patient infection averted ranges from $29 807 000 under a low-risk scenario to a savings of $81 000 under a high-risk scenario. Conclusion.-Our analysis neither justifies nor precludes a mandatory testing policy. Further research on the key data inputs is needed. Given the ethical, social, and public health implications, mandatory testing policies should not be implemented without greater certainty as to their cost-effectiveness.
引用
收藏
页码:851 / 858
页数:8
相关论文
共 50 条
  • [21] RISK AND COST-EFFECTIVENESS ANALYSIS OF UNITED-STATES GUIDELINES RELATIVE TO RADIOACTIVITY IN FOODS
    SHLEIEN, B
    HEALTH PHYSICS, 1975, 29 (02): : 307 - 312
  • [22] A review of the cost-effectiveness of interventions to prevent sexual transmission of HIV in the United States
    Pinkerton S.D.
    Johnson-Masotti A.P.
    Holtgrave D.R.
    Farnham P.G.
    AIDS and Behavior, 2002, 6 (1) : 15 - 31
  • [23] Cost-effectiveness of tipranavir in treatment-experienced HIV patients in the United States
    Simpson, Kit N.
    Roberts, Graeme
    Hicks, Charles B.
    Finnern, Henrik W.
    HIV CLINICAL TRIALS, 2008, 9 (04): : 225 - 237
  • [24] SCREENING ADOLESCENTS AND YOUNG ADULTS FOR HIV IN THE UNITED STATES: A COST-EFFECTIVENESS ANALYSIS
    Neilan, Anne
    Dunville, Richard
    Ocfemia, M. Cheryl Banez
    Salomon, Joshua
    Francke, Jordan
    Wang, Li Yan
    Bulteel, Alex
    Hsu, Kathy
    DiNenno, Elizabeth
    Parker, Robert
    Walensky, Rochelle
    Freedberg, Kenneth
    Ciaranello, Andrea
    JOURNAL OF ADOLESCENT HEALTH, 2017, 60 (02) : S18 - S18
  • [25] Cost-effectiveness analysis in the United States - Reply
    Pearson, SD
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (23): : 2722 - 2723
  • [26] Update on the cost-effectiveness of contraceptives in the United States
    Trussell, James
    Sinai, Irit
    CONTRACEPTION, 2010, 82 (04) : 391 - 392
  • [27] Cost-Effectiveness of Hormone Therapy in the United States
    Lekander, Ingrid
    Borgstrom, Fredrik
    Strom, Oskar
    Zethraeus, Niklas
    Kanis, John A.
    JOURNAL OF WOMENS HEALTH, 2009, 18 (10) : 1669 - 1677
  • [28] DISTRIBUTION OF DENTISTS IN THE UNITED-STATES
    不详
    JOURNAL OF THE AMERICAN DENTAL ASSOCIATION, 1949, 39 (04): : 489 - 492
  • [29] Cost-effectiveness of enfuvirtide in HIV therapy for treatment-experienced patients in the United States
    Hornberger, J
    Kilby, JM
    Wintfeld, N
    Green, J
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2006, 22 (03) : 240 - 247
  • [30] Cost-effectiveness of expanded hepatitis A vaccination among adults with diagnosed HIV, United States
    Abimbola, Taiwo O.
    Van Handel, Michelle
    Tie, Yunfeng
    Ouyang, Lijing
    Nelson, Noele
    Weiser, John
    PLOS ONE, 2023, 18 (03):